Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, March 9, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in March, following the publication of year-end 2021 results, the release of additional positive Phase II COVID-19 results, and the announcement of the plan to initiate a regulatory validated Phase III trial within the first half of 2022 for the ABNCoV2 vaccine. Analysguiden set a new price target of SEK 39, based on a revised forecast of market size and price per dose, while acknowledging that a more optimistic scenario results in a fair value of at least SEK 80.
The research report is available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website. The next update from Analysguiden is expected following major news.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se